Considering Systemic Administration of PPARalpha Agonist for the Treatment of Diabetic Retinopathy & AMD
Time: 4:00 pm
day: Conference Day One
Details:
- Understanding PPARa as a drug target for diabetic retinopathy
- Exploring novel non-fibrate PPARalpha agonists with higher potency and selectivity for PPARalpha agonism
- Demonstrating the effects on retinal degeneration, inflammation and neovascularization in diabetic and AMD animal models
